Dr. Eric Dube: So, Bill, I’ll have you comment on the regulatory perspective and how we are thinking about the totality of data and Peter you can talk about directionally what we’re seeing in October as well as conversion bill.
Dr. Bill Rote: Certainly, thanks for the questions, Ed. I thought that was a very good session on IgA nephropathy endpoints and, and the question was put to Dr. Thompson about how is the agency looking at assessing all the different drugs that are in Phase 3 studies now for approval or moving toward that. And her remarks, one, they were very consistent with the discussion that we’ve had over the years around endpoints that there are different ways to measure kidney function. eGFR, she pointed out is a surrogate in itself, but it’s a validated surrogate. And for those patients with a high risk of kidney progression, they want to see a compound showing a meaningful effect on the rate of loss across the body of evidence. And they’re also looking for compounds that show an accumulation of benefit across various stages of the disease, whether they are early in the disease progression or later in that.
And I think that the data package that we have with the chronic slope, the total slope measurements pre and post, the overall absolute difference at two and a half years, the reduction in hard endpoints, the kidney failure endpoints, the increase in patients that get to complete remission. All of this on a background of a very safe therapy, it’s clear, mechanistically, there’s two things going on in these kidneys, angiotensin and endothelium, both driving negative effects and blockade of both together. It’s really required to have the best outcomes in these patients. So, I’m very confident in the fact that we have a very strong case to make with the agency. And I look forward to the review.
Dr. Eric Dube: Alright. Peter, would you like to comment on direction of what we’re seeing in October and the conversions which we’re not providing metrics on, but directionally?
Peter Heerma: Yes, I would say to your point Eric, we have to practice not to commend on metrics. Within the quarter with regards to demand, I would say that we see a continuation of new patient source forms coming in, so really pleased with that. And also to what I mentioned in the prepared remarks, we start to see like the increase in patient-ship. So, I’m really pleased with the progress and also expect to have that further inflection on revenue in first quarter and moving into 2024.
Operator: And that does conclude the question and answer session. I’ll hand the call back over to you.
Dr. Eric Dube: Thank you everyone for joining us for our third quarter 2023 financial results call. We look forward to providing additional updates on our progress. Have a great rest of your day and thank you.
Operator: Thank you. And that does conclude today’s conference. We do thank you for your participation and have an excellent…
